Acquired genetic abnormalities play an essential role in leukemogenesis and are one of the most important prognostic factors in acute myeloid leukemia (AML). To investigate whether there are some distinctions in genetic alteration profiles among different human races, data from several prospective AML trials were retrospectively analyzed. The ratio of core binding factor (CBF) leukemia in our cohort (ChiCTR-TRC-10001202) is 27.7%. Similarly, the ratios are 22.1, 21.1, and 23.4%, respectively, from Chinese, Korean, and Japanese, the other three Eastern Asian AML cohorts \[[@CR1]--[@CR3]\]. However, the CBF leukemia constitutes 15.5, 12.5, 9.3, 10.2, and 12% of patients, respectively, in ECOG1900, MRC AML15, UK NCRI AML17, HOVON/SAKK AML-42, and German AML2003(Additional file [1](#MOESM1){ref-type="media"}: Table S1) \[[@CR4]--[@CR8]\]. All of the latter cohorts are from European or American countries. Therefore, CBF leukemia occurs more frequently in Eastern Asian countries than in European and American countries. Meanwhile, the proportion of NPM1 is 15.9 and 13.3%, respectively, in our cohort and another Chinese one \[[@CR3]\] (Additional file [1](#MOESM1){ref-type="media"}: Table S2). The proportions of FLT3-ITD mutation are 11.2 and 13.0%, respectively, in our cohort and another Chinese one \[[@CR3]\] (Additional file [1](#MOESM1){ref-type="media"}: Table S3). Whereas, NPM1 mutation ratios are 27.9, 29.0, and 33.0%, respectively, in MRC AML15, UK NCRI AML17, and German AML2003. FLT3-ITD mutation occurs at 24.6 and 17.9%, respectively, in MRC AML15 and UK NCRI AML17 (Additional file [1](#MOESM1){ref-type="media"}: Table S2 and S3) \[[@CR5], [@CR6], [@CR8]\]. These data demonstrate that NPM1 and FLT3-ITD mutations are less common in Chinese AML patients in comparison with cases from Europe. It indicates that there are some differences in the frequencies of genetic alteration between Caucasian and Eastern Asian population.

The bias of these comparisons result from the fact that patients from Chinese and Korean cohorts are younger than those from European and American cohorts. To eliminate this bias, we only compared the molecular mutation constitution from patients younger than who were 40 years old in MRC AML10 and AML12 \[[@CR9]--[@CR12]\]. As shown in Table [1](#Tab1){ref-type="table"}, all of the molecular mutations, except FLT3-TKD, are significantly different between MRC cohorts and ours. After excluding the age bias, the ratio of FLT3-ITD mutation is still higher in MRC cohorts, which is similar to the results based on the entire cohorts. And there are more DNMT3a mutations and less CEBPA mutations in MRC cohorts.Table 1Molecular mutation ratios of patients younger than 40 years old in MRC AML10 and AML12 and our cohortMRC AML10 and AML12China1^a^*P* value (MRC vs. China1)Age range, yearsMUT, no.WT, No.MUT/total, %Median age (range), yearsMUT, no.WT, No.MUT/total, %FLT3-ITD \[[@CR9]\]15--346822223.436 (15--55)6652211.2\< 0.001FLT3-TKD \[[@CR10]\]15--394641210.036 (15--55)515348.720.464DNMT3a \[[@CR11]\]15--397128719.836 (15--55)383489.84\< 0.001CEBPA \[[@CR12]\]15--39495248.636 (15--55)11644220.8\< 0.001CEBPA double \[[@CR12]\]15--39335405.836 (15--55)7548313.4\< 0.001CEBPA single \[[@CR12]\]15--39165572.936 (15--55)415177.3\< 0.001*Abbreviations*: *WT* wild type, *MUT* Mutant^a^Data from our cohort (ChiCTR-TRC-10001202)

In order to further confirm that these differences were not due to the onset of age, we analyzed the data in patients older than 40 or 50 years old from Chinese and Japanese trials and compared with Caucasian data. As shown in Additional file [1](#MOESM1){ref-type="media"}: Table S4, the frequency of FLT3-ITD in patients older than 40 years old from Chinese trial is only 11.5% which is still significantly lower than that in MRC AML15 and UK NCRI AML17 trial (24.6 and 17.9%, respectively) \[[@CR5], [@CR6]\]. There are 24.4 and 18.7% CBF leukemia in patients older than 40 or 50 years old of Chinese and Japanese trials, respectively. They are all significantly higher than those from Caucasian trials, except that the difference between Japanese trials and ECOG1900 did not reach the threshold of statistical significance (Additional file [1](#MOESM1){ref-type="media"}: Table S5). NPM1 mutation occurs in 23.6% patients older than 40 years old from Chinese trial. It is still lower than Caucasian data, although there is only statistically difference in comparison with German AML2003 (*P* = 0.005) (Additional file [1](#MOESM1){ref-type="media"}: Table S6). These data suggest that AML patients older than 40 years old still had distinctions in frequencies of CBF and FLT3-ITD alterations, which is similar to the difference among the entire cohorts.

As we know, CBF alteration comprises CBFbeta-MYH11 and AML1-ETO fusion genes. Therefore, we finally compared and contrasted the CBF leukemia constitution between Eastern Asian and Caucasian trials. As shown in Table [2](#Tab2){ref-type="table"}, CBFbeta-MYH11 occurred in 50.0 and 54.3% of CBF leukemia in HOVON/SAKK AML- 42 and ECOG1900 trials, respectively \[[@CR4], [@CR7]\]. There are only 20.1 and 20.8% CBFbeta-MYH11 in Chinese and Japanese trials, respectively \[[@CR13]\], which are significantly lower than Caucasian data. We also calculated the frequencies in older patients in Eastern Asian trials. The CBFbeta-MYH11 ratios are 25.9 and 20.2% in AML patients older than 40 or 50 years old in Chinese and Japanese trials, respectively, which are also significantly lower than that in HOVON/SAKK AML- 42 and ECOG1900 trials and similar to the results of the entire cohort analysis (Table [2](#Tab2){ref-type="table"}). These data indicate that both CBF leukemia frequencies and CBF leukemia constitutions are distinct between Eastern Asian and Caucasian trials, not only in the entire cohorts but also in post hoc analysis after excluding the age bias. We followed the outcome of all these cohorts after we found different mutation landscape. But we only showed, but did not compare the outcome between these cohorts since it is too complicated to compare the outcomes when patients received different therapies (Additional file [1](#MOESM1){ref-type="media"}: Table S7).Table 2CBF leukemia constitution in Japanese and Chinese cohorts against European and American cohortsChina1^a^JALSG AML95, 97, and 201 \[[@CR13]\]China1^a^JALSG AML95, 97, and 201 \[[@CR13]\]HOVON/SAKK AML- 42 \[[@CR7]\]ECOG1900 \[[@CR4]\]Median age, years36--46--4948Age range, years15--5515--6440--5550--6417--6017--60CBFβ-MYH11, no.3310715344457AML1-ETO, no.131408431344448CBFβ-MYH11 in CBF (%)20.120.825.920.250.054.3*P* value (vs. ECOG1900)\< 0.001\< 0.001\< 0.001\< 0.0010.553*P* value (vs. HOVON/SAKK AML- 42)\< 0.001\< 0.0010.004\< 0.0010.553^a^Data from our cohort (ChiCTR-TRC-10001202)

All these data indicate that the different incidence of patterns of mutation acquisition exists between Caucasian and Eastern Asian population, suggesting that genetic backgrounds have an impact on leukemogenesis. We think that these differences become more and more important and are needed to be further investigated, since many novel drugs, such as FLT3 and IDH2 inhibitors, target on genetic mutations and the effectiveness may depend on patterns of mutation acquisition.
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